Navigation Links
Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1

eating chronic hepatitis C is combination therapy consisting of pegylated alpha interferon and ribavirin.

About Diabetes

Diabetes affects more than 20 million in the United States and an estimated 194 million adults worldwide. Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the United States. According to the U.S. Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve target A1c levels with their current treatment regimen.

DUROS is a registered trademark of ALZA Corporation (Mountain View, CA) licensed to Intarcia Therapeutics, Inc. Intarcia and its logo are trademarks of Intarcia Therapeutics, Inc. (Emeryville, CA).

CONTACT: James Ahlers, Chief Financial Officer of Intarcia Therapeutics,+1-510-652-2600, ext. 235

Web site: http://www.intarcia.com/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4

Related medicine technology :

1. Intarcia Therapeutics Announces Presentation of Final Results From a Phase 2 Combination Study for the Treatment of Hepatitis C at the Digestive Disease Week Conference
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:10/10/2008)... WALTHAM, Mass., Oct. 10 /PRNewswire-FirstCall/...A ), a leading provider of near-patient,diagnostic... yesterday with,Ban Ki-moon, the Secretary-General...or executives of seventeen of the world,s leading,...nostic companies.,Inverness, together with senior ...
(Date:10/10/2008)... PLEASANTON, Calif., Oct. 10 /- Tr...as been authorized to affix the CE (Conformite,Eur...ntares(TM) Coronary,Stent System, a unique main ve... near coronary bifurcations., Representing the ne...(TM) system has potential use in a quarter of the ...
(Date:10/9/2008)... World Sight Day 2008 focuses on the need to pr.... 9 /- Of the 45 million people world...d three-quarters of them could,have avoided their ...reated., To view the Multimedia News Release, go ... Alcon, the world,s leader in eye care products an...
(Date:10/9/2008)... Top Line Clinical Results Expected in November...ll/ -- SCOLR Pharma, Inc.,(Amex: DDD ) announced ...ing,for the third of its three pivotal trials to e... of 12-hour extended-release (ER) ibuprofen for,th...ts to report top-line,results from this pivotal tr...
Breaking Medicine Technology:Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 2Inverness Medical Innovations Participates in Meeting on HIV/AIDS with UN Secretary-General 3TriReme Medical Inc. Receives CE Marking for Antares(TM) Coronary Stent System 2ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 1Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 2Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board 4343 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 1EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 2EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 3EntreMed Commences Continuous Dosing Clinical Trial For MKC 1 1672 4China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 1China Bionanometer Industries 28CBIU 29 Describes their Current Production Capacity and Product Lines 15734 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 1Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 2Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 3Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 4Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 5Massachusetts Health Quality Partners Issues 2008 Report on Quality of Care 15732 6
...TTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scien...esults of its Phase III,AIR-CF2 study evaluating a...patients with cystic fibrosis (CF) who have,pulmon... study, a,28-day treatment course of aztreonam lys...haled or intravenous (IV) antibiotics versus,place...
...VER--(BUSINESS WIRE)--Apr 23, 2007 - Ceragenix Pha...al company focused on,infectious disease and derma...rch paper on two of the Company,s antimicrobial,co...he April issue,of the Journal of Antimicrobial Age...rnal of the American Society of,Microbiology, dedi...
Other Medicine Technology:Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 2Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 3Ceragenix Announces New Publication of Scientific Research on,Ceragenin Technology 4
(Date:10/13/2008)...eading Content Rights Management System, Supports... Content Spend, WEST CHESTER, Pa., Oct. 13 /PRNew...ding global pharmaceutical manufacturer has integr...primary platform for the,secure distribution, data...cs for their new product video content. Imperium i...
(Date:10/13/2008)...swire/ -- The National Coalition for,Quality Color...ncerns over,the National CT Colonography Study pub...Medicine. The evidence must be closely evaluated, ...y is not without significant,potential risks. The ...py,remains the "Gold Standard" for colorectal canc...
(Date:10/13/2008)...blem in daily life, survey shows, PORTLAND, Ore.,...three-quarters of people living with psoriasis say...e, according to a National Psoriasis,Foundation 20...viduals with psoriasis and psoriatic arthritis,als...ly lives, shapes their,feelings about themselves a...
(Date:10/13/2008)...swire/ -- During the Pri-Med New York,conference a...are providers,took a 20-question quiz prepared by ...n Somerset, NJ. The quiz tested basic knowledge of..., EMR software, and healthcare,administration., T... The average number,of correct answers was only 7....
Breaking Medicine News(10 mins):Health News:Global Pharma Integrates Imperium(TM) to Support Launch Content ROI Initiatives! 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 2Health News:National Coalition for Quality Colorectal Cancer Screening and Care Conveys Concerns over CT Colonography 3Health News:National Psoriasis Foundation Releases 2008 Study Results 2Health News:MTBC Practice Management Quiz Sends Message to Doctors: There is Real Room for Improvement or a Need to Outsource 2
...hearts from donors 50 years of age and older appea... younger patients, according to a University Of Al...e Journal of Cardiac Surgery, March-April 200...d the results of using heart donors 50 years of ag...
...esearchers has highlighted that most of the US men...equired// for follow up tests done to evaluate the...6 men who underwent vasectomy at the Cleveland Cli...o attend the two-sets of sperm-checking tests, tha...
...plying antiviral coating on bank notes, vending ma...n fighting the epidemics//. Materials researcher ...ondon, has discovered a coating of metal, metal ox...strong antiviral properties, reported the online e...
...te by goths — a group fascinated by the darker sid...rm and suicide attempts//. University of Glasgo... young adults several times throughout their teen ...ens who said they were goths admitted to self-harm...
Other Medicine News:Health News:Men Unaware of Fertility Status After Vasectomy 2
Gentamicin Reagent Solution (10 mg/ml) liquid
LB Agar plates with 0.1mM EDTA.
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride.
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride.
Medicine Products: